Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568358 | 0.92 | GAA (0.42) | RAB9ANPC1MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL4568361 | 0.90 | TAS1R3 (0.41) | RAB9ANPC1MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL4568068 | 0.89 | TAS1R3 (0.50) | RAB9ANPC1MAPTSMN1; SMN2CYP17A1 | |
| SCHEMBL4568054 | 0.87 | SMN1; SMN2 (0.47) | RAB9ANPC1MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL4568362 | 0.86 | CYP17A1 (0.37) | RAB9ANPC1MAPTSMN1; SMN2EPHX2 | |
| SCHEMBL4568052 | 0.86 | NPC1 (0.46) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL4568062 | 0.85 | MEN1 (0.45) | NPC1MAPTSMN1; SMN2LMNATP53 | |
| SCHEMBL4568049 | 0.84 | RAB9A (0.46) | RAB9ANPC1MAPTSMN1; SMN2LMNA | |
| SCHEMBL4568051 | 0.84 | KCNK3 (0.45) | RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4568067 | 0.84 | KMT2A (0.50) | RAB9ANPC1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | RAB9A 1646/4885NPC1 1150/4885MAPT 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.